

Giacomo Pelizzari

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7767321/giacomo-pelizzari-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

41
papers

344
citations

12
h-index

17
g-index

64
ext. papers

470
ext. citations

4
avg, IF

3.29
L-index

#	Paper	IF	Citations
41	A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021 , 1185, 122985	3.2	2
40	First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. <i>Breast</i> , 2021 , 57, 104-112	3.6	2
39	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
38	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , 2021 , 40, 286-294	5.9	8
37	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021 , 34, 550-563	4.5	2
36	Feasibility and Predictive Performance of a Triage System for Patients with Cancer During the COVID-19 Pandemic. <i>Oncologist</i> , 2021 , 26, e694-e703	5.7	3
35	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	12
34	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 661-668	5.7	6
33	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. <i>Future Oncology</i> , 2020 , 16, 2059-2073	3.6	1
32	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application. <i>PLoS ONE</i> , 2020 , 15, e0228822	3.7	11
31	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. <i>Scientific Reports</i> , 2020 , 10, 7010	4.9	8
30	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020 , 16, 2645-2660	3.6	1
29	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. <i>Drugs and Aging</i> , 2020 , 37, 677-689	4.7	1
28	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		
27	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		
26	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		
25	Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application 2020 , 15, e0228822		

24	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. <i>Cancers</i> , 2019 , 11,	6.6	17
23	Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. <i>Cancers</i> , 2019 , 11,	6.6	41
22	The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019 , 10, 368-377	10.3	36
21	Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
20	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5564-5564	2.2	1
19	Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 577-577	2.2	
18	Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. <i>Melanoma Research</i> , 2019 , 29, 510-515	3.3	8
17	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. <i>Cancer Treatment Reviews</i> , 2019 , 72, 7-14	14.4	12
16	Atezolizumab for the treatment of breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 595-603.	3.4	12
15	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. <i>Breast</i> , 2018 , 40, 45-52	3.6	4
14	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <i>Future Oncology</i> , 2018 , 14, 849-859	3.6	13
13	Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13079-e13079	2.2	2
12	Association of clinical factors and biological subtypes with different Ca15-3 levels in metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e24014-e24014	2.2	
11	Integration of lymphocyte ratios (LRs) and circulating tumor cells (CTCs) characterization: The interplay between immunity and metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12039-12039	2.2	
10	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018 , 18, 932	4.8	2
9	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 365-374	5.4	23
8	Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. <i>Cancer Treatment Reviews</i> , 2017 , 61, 15-22	14.4	30
7	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12010-e12010	2.2	

6	A novel MGMT methylation-based prognostic score in patients with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2048-2048	2.2	
5	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyPhysicians inform oncological patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21632-e21632	2.2	
4	Risk of unplanned presentations and hospital admission in lung cancer patients: Insights from the experience of a single institution.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e21601-e21601	2.2	
3	Screening with low-dose computed tomography (LDCT) of asbestos-exposed subjects and lung cancer (LC) mortality.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1554-1554	2.2	
2	Do platinum salts fit all triple negative breast cancers?. <i>Cancer Treatment Reviews</i> , 2016 , 48, 34-41	14.4	38
1	Central nervous system involvement in breast cancer patients: Is the therapeutic landscape changing too slowly?. <i>Cancer Treatment Reviews</i> , 2016 , 46, 80-8	14.4	16